Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisers, the drug ‘donanemab’ would only be the second Alzheimer’s drug cleared in the United States. to slow cognitive decline due to Alzheimer’s. Katherine Ward has this story and more in Health Matters for June 11, 2024.
Health Matters
Health Matters: U.S. FDA advisers endorse Alzheimer’s drug
More Videos
-
Health Matters: Dozens sickened after eating BC oysters
-
Health Matters: Nestle launches protein shots in U.S.
-
Health Matters: Canada Post workers seek improved health and safety measures on the job
-
Health Matters: LGBTQ2 advocates try to halt Alberta’s transgender bill
-
Cancer costs a patient $33K, Canadian Cancer Society report says
-
Health Matters: Alberta signs onto federal deal for rare disease drugs
You are viewing an Accelerated Mobile Webpage.
View Original Article